Danish Drama: Genmab Drops $8B on Cancer Cure Hope Seller
In a move that screams 'we have billionaire money to burn,' Danish biotech bigwig Genmab announced it plans to acquire Merus, the brainiac behind a shiny new head and neck cancer drug, for around $8 billion. That's $8 billion, or roughly the cost of buying every Danish pastry in Copenhagen twice over. This deal lands Genmab firmly in Life Sciences prime, scheming to turn biology into cold, hard kroner. With cancer therapy innovation like this on the line, letâs hope Merus's drug fights neck and head tumors better than Genmab fought that price tag.
Share the Story
(1 of 3)Genmab just dropped $8 billion on Merus like itâs Black Friday for biotech, apparently 'saving cancer patients' is easier when you have a billionaire bankroll appearing out of nowhere.
Buying a head and neck cancer drug developer for $8 billion is peak pharmaceutical flexâGenmabâs basically saying, 'Weâll fix your cells, but first, show us the money.'
Genmab buying Merus is like paying $8 billion for a Tesla upgradeâyouâre still hoping it doesnât break down, but hey, it looks promising!
Source: Statnews | Published: 9/29/2025 | Author: Andrew Joseph
More Articles in Business
Motorola Razr Flip Phones Finally Told Theyâre Secure Enough for 2027
America Tries Staying Cool While Secretly Preparing For Wattocalypse
Canada Declares 'No American Goods' After US Says '50% More Please'
US and Canada Start Tariff Edition of Chips Ahoy Costume Party
Zillow Pays Redfin to Not Compete, Then Both Pupils Graduate Antitrust Class
KPMGâs Consulting Business Dies Dramatically While Staff Take a Hike
Man Applies to 200 Jobs with AI's Help, Still Does Own Eyerolling
